Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label Study.

Saved in:
Bibliographic Details
Title: Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label Study.
Authors: Joyce JC; Division of Dermatology, Department of Medicine, Endeavor Health, 9933 Woods Drive, Suite 100, Skokie, IL, 60077, USA. joel.joyce@endeavorhealth.org., Hong HC; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.; Probity Medical Research, Surrey, BC, Canada., Siri DD; Sneeze, Wheeze, and Itch Clinical Research Center, Normal, IL, USA., Toth D; Probity Medical Research, Windsor, ON, Canada., Kallender H; Incyte Corporation, Wilmington, DE, USA., Kuo Y; Incyte Corporation, Wilmington, DE, USA., Stefani-Hunyady D; Incyte Corporation, Wilmington, DE, USA., Papp KA; Probity Medical Research, Waterloo, ON, Canada.; Division of Dermatology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.; Alliance Clinical Trials, Waterloo, ON, Canada.
Source: American journal of clinical dermatology [Am J Clin Dermatol] 2026 Jul; Vol. 27 (4), pp. 841-849. Date of Electronic Publication: 2026 May 27.
Publication Type: Journal Article; Clinical Trial, Phase III; Multicenter Study
Journal Info: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 100895290 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1888 (Electronic) Linking ISSN: 11750561 NLM ISO Abbreviation: Am J Clin Dermatol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1179-1888
DOI:10.1007/s40257-026-01043-0